clinical trial · NCT05502237
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Gilead Sciences·phase3·active not recruiting·n = 1,021
Non-small Cell Lung CancerZimberelimabDomvanalimabPembrolizumabCarboplatinCisplatinPaclitaxelNab-paclitaxelPemetrexed
brief summary
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
started
Oct 12, 2022
primary completion
Jun 1, 2028
completion
Jan 1, 2029
last updated
Jan 30, 2026
official title
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol